Introduction
The initial growth of solid tumors is not well coordinated with the formation of new blood vessels necessary to support malignant expansion (Folkman et al., 1966) . Thus, tumors rapidly outstrip the existing vasculature, resulting in a microenvironment restricted for critical nutrients (glucose and oxygen). Limitation of glucose and oxygen is cytotoxic as production of adenosine-5 0triphosphate through glycolysis and reducing equivalents in the form of nicotinamide adenine dinucleotide phosphate become hampered, whereas reactive oxygen species (ROS) are generated in the mitochondria (Brunelle et al., 2005; Guzy et al., 2005) . Thus, nutrient-poor tumor microenvironment could have a profound effect on cancer cell energy metabolism and redox homeostasis (Spitz et al., 2000; DeBerardinis et al., 2008) .
Cellular energy and redox homeostasis is critical for proper folding and modification of transmembrane and secreted proteins within the endoplasmic reticulum (ER). Perturbation of this homeostasis triggers a cellular checkpoint referred to as the unfolded protein response. The capacity of the ER to respond to alterations in nutrient status makes it an effective early sensor of cellular stress associated with tumorigenesis. The unfolded protein response is mediated by three primary signal transducer molecules that span the ER membrane: RNA-dependent protein kinase (PKR)-like ER kinase (PERK/PEK/EIF2AK3; Shi et al., 1998; Harding et al., 1999) , inositol-requiring enzyme 1 (Ire1a and Ire1b; Tirasophon et al., 1998; Wang et al., 1998) and transmembrane activating transcription factor 6 (ATF6; Haze et al., 1999; Li et al., 2000; Wang et al., 2000) . Together, PERK, Ire1 and ATF6 alleviate ER stress by regulating expression of ER chaperones and components of ER-associated degradation system (Wu et al., 2007; Yamamoto et al., 2007) , whereas PERK uniquely serves to reduce new protein synthesis. If stress is severe, unfolded protein response sensors trigger apoptotic program to eliminate damaged cells.
PERK is a transmembrane serine/threonine protein kinase that phosphorylates two known substrates: the eukaryotic translation initiation factor 2a (eIF2a; Harding et al., 1999) and the Nrf2 (nuclear factor (erythroid-derived 2)-like 2) transcription factor (Cullinan et al., 2003) . Phosphorylation of eIF2a attenuates translation initiation of most transcripts while concurrently increasing translation of select mRNAs such as the ATF4 transcription factor (Harding et al., 2000; Vattem and Wek, 2004) . PERK-dependent attenuation of protein synthesis results in decreased consumption of reducing equivalents necessary for the disulfide bond formation during oxidative folding in the ER (Shimizu and Hendershot, 2009 ). PERK-dependent resistance to oxidative stress is further regulated by ATF4 (Harding et al., 2003) . Finally, phosphorylation of Nrf2 by PERK (Cullinan et al., 2003) leads to the induction of enzymes critical for the elimination of intracellular ROS (Itoh et al., 1997; Alam et al., 1999; Wild et al., 1999; Hayes et al., 2000) . Thus, PERK function is critical for maintaining cellular redox homeostasis and preventing ROS-induced genotoxic stress.
Initial findings implicated PERK as antitumorigenic regulator, as PERK deficiency inhibited the ability of Ras-transformed mouse embryonic fibroblasts to grow as subcutaneous transplants (Bi et al., 2005; Blais et al., 2006) . However, subsequent studies revealed that overexpression of a dominant-negative PERK allele in MCF10A normal mammary epithelial cells rendered neoplastic growth characteristics (Sequeira et al., 2007) . In addition, activation of Fv2E-PERK engineered to contain a drug-inducible dimerization domain reduced tumorigenic potential of squamous carcinoma T-HEp3 cells and SW620 colon carcinoma cells (Ranganathan et al., 2008) . Finally, activation of PERK by overexpression of H-Ras in melanocytes was associated with a senescent phenotype (Denoyelle et al., 2006) , suggesting that PERK may function as a barrier to malignant growth in certain contexts.
In this study, we interrogated the importance of PERK for tumorigenesis using short hairpin RNA (shRNA) approach to reduce PERK levels in human breast and esophageal carcinoma cells. In addition, we generated a mammary gland-specific knockout of PERK in the mammary tumor-prone MMTV-Neu mouse strain. Our results reveal that loss of PERK renders tumor cells acutely susceptible to oxidative DNA damage. The subsequent induction of the DNA damage checkpoint significantly reduces tumor cell growth in vitro and in vivo.
Results

PERK is expressed in cancer cells in which it potentiates tumor expansion
Markers of ER stress signaling, including phospho-eIF2a and GRP78 expression, are increased in a variety of tumors (Gazit et al., 1999; Fernandez et al., 2000; Daneshmand et al., 2007; Lee et al., 2008) . Because PERK mediates cell growth and survival under conditions of ER stress, we determined whether tumor-derived cells retain functional PERK. We assessed PERK expression in four breast and three esophageal human carcinomaderived cell lines and compared it with the PERK levels in MCF10A cells, which is an immortalized, nontransformed breast epithelial cell line. Functional PERK protein was readily detectable in all cell lines (Figures 1a and c) . To assess the role of PERK in human tumor cell growth and survival, we used lentivirus-delivered shRNAs to reduce endogenous levels of PERK (Figure 1b ), which also resulted in attenuated activation of PERK effectors such as ATF4/CHOP in MDA-MB468 cells challenged with tunicamycin ( Figure 1c ).
To determine whether PERK deficiency affects the ability of mammary carcinoma cells to form solid tumors in vivo, we used tumor-prone MMTV-Neu transgenic mice bearing PERK loxP/loxP allele (MMTV-Neu/PERK loxP/loxP ). Primary tumor cells isolated from MMTV-Neu/PERK loxP/loxP mice were transduced with empty vector retrovirus or retrovirus encoding Cre recombinase to excise perk (Figure 1e ), and then transplanted into mammary fat pads of 3-week-old severe combined immunodeficient mice. During a 28day interval, PERK-deficient cells generated tumors with a significantly reduced volume relative to PERKpositive cells (Figure 1d ). Similar reduction in tumor volume was observed upon PERK knockdown in human MDA-MB468 cells (Supplementary Figure S1 ). These data collectively show a role for PERK as a critical regulator of mammary tumor expansion.
Loss of PERK in human cancer cells delays cell cycle progression
Gain and loss of PERK function can influence cell cycle progression (Zhang et al., 2006b; Wei et al., 2008) . Accordingly, subsequent to acute PERK knockdown in MDA-MB468 and T47D cells, we noted a 50% reduction in 5-bromodeoxyuridine-incorporating S-phase cells with a concomitant increase in G2/M population and a small increase in cell death (Figure 2a and Supplementary Figure S2A ). Thus, knockdown of PERK triggers a cell cycle delay at the G2/M boundary, resulting in a significant decrease in cancer cell proliferation in vitro.
To confirm this, we measured growth rates of stable PERK knockdown cells relative to parental cells using three different human carcinoma cell lines derived from two distinct cancer types. Strikingly, PERK knockdown resulted in a significant reduction in the growth rate of human breast carcinoma MDA-MB468 ( Figure 2b ) and T47D (Supplementary Figure S2B ) cells, as well as esophageal carcinoma TE3 cells (Supplementary Figure  S2C ). To ensure that the reduced growth kinetics specifically reflected reduced levels of PERK, we restored PERK function by transducing cells with retrovirus encoding myc-tagged murine PERK that is refractory to shRNA ( Figure 2b ). Murine PERK restored tunicamycin-dependent induction of ATF4 and CHOP ( Figure 1c ) and resulted in a significant rescue of attenuated cell growth (Figure 2b ). To determine whether attenuated proliferation after loss of PERK function is restricted to tumor cells, we determined whether excision of perk in normal mammary epithelium inhibits proliferation. Critically, perk excision in mammary epithelial cells did not influence their proliferative capacity (Figures 2c and d) .
The G2/M cell cycle delay/arrest is frequently associated with the activation of a DNA double-strand break (DSB) checkpoint. Thus, we next tested for the evidence of DNA damage response (DDR) pathway activation. Indeed, acute PERK knockdown coincided with accumulation of phospho-ATM and phospho-Chk2-positive foci in MDA-MB468 (Figures 3a and b) and T47D cells (Supplementary Figure S3A and B). Coordinately, we noted increased phospho-Chk2 and pTyr-15 on CDK2 ( Figure 3c ) as well as a 20% reduction in CDK2 ( Figure 3d ) and CDK1 (data not shown) kinase activity, although somewhat reduced CDK2 protein levels. The CDK1/2 activity could be restored by introduction of murine PERK (Figure 3d and data not shown). In addition, we noted a significant inhibition of CDK2 activity in a lysate prepared from tumor in which PERK was excised (Supplementary Figure S3C ). Finally, acute PERK knockdown did not result in a cell cycle delay in human colorectal carcinoma HCT116 cells (Supplementary Figure S3D ) that have reduced ataxia telangiectasia mutated (ATM) levels because of the promoter hypermethylation (Kim et al., 2002) . However, a G2/M delay was observed in HCT116 cells deficient for ATM/ataxia telangiectasia and Rad3 related (ATR) downstream target Chk2 concomitant with decreased levels of Chk1 (Supplementary Figure S3 D and E), suggesting that the ATR/Chk1 axis was activated (Zhang et al., 2005 (Zhang et al., , 2009 ). Thus, acute loss of PERK delays progression 
ROS accumulate in PERK-deficient cells
Previous work revealed a role for PERK in the regulation of cellular redox homeostasis through direct phosphorylation of Nrf2 (Cullinan et al., 2003; and translational regulation of ATF4 (Harding et al., 2003) . We thus determined whether PERK loss contributed to increased cellular ROS in human breast carcinoma cells. Indeed, PERK knockdown led to significantly increased levels of ROS (Figures 4a and b ). Furthermore, growth curve analysis in the presence of ROS scavenger, N-acetylcysteine, revealed that ROS accumulation contributed to reduced cell growth in PERK knockdown cells ( Figure 4c ).
ROS accumulation triggers oxidative DNA damage
To determine whether PERK loss and subsequent accumulation of ROS triggers oxidative DNA damage, we quantified 8-oxoguanine adducts, an oxidation product of guanine. PERK knockdown resulted in a significant increase in 8-oxoguanine adducts relative to After DNA damage, H2AX, a histone H2 variant, is phosphorylated around regions of DSBs by the phosphoinositide 3-kinase family members ATM and ATR, and it accumulates in DNA repair foci in which it contributes to the recruitment of DNA repair proteins (Bassing and Alt, 2004) . We thus measured the accumulation of phosphorylated H2AX, g-H2AX, as a surrogate marker for the formation of DSBs. A twofold increase in g-H2AX was noted in PERK knockdown cells relative to parental cells and/or cells infected with an empty vector (Figures 6a and b) . Critically, we also noted increased levels of g-H2AX-positive cells in PERK-deficient tumors in vivo (Supplementary Figure  S4 A and B) . As g-H2AX is also thought to accumulate under conditions not associated with DSBs, we assessed the accumulation of damaged DNA through the use of a COMET assay. Indeed, PERK knockdown triggered accumulation of cells with pronounced tail moment ( Figure 6c ).
Although activation of a DSB checkpoint typically results in a transient arrest and cell cycle restart after repair, it is also associated with cellular senescence. However, increased accumulation of p19 Arf and trimethylated H3K9 was not observed in PERK-deficient tumors, suggesting that loss of PERK does not induce a senescent phenotype (Supplementary Figure S4C) . Reduced activity of Nrf2 leads to increased oxidative stress in PERK knockdown cells Nrf2, a direct PERK substrate (Cullinan et al., 2003) , contributes to the transcriptional regulation of genes whose protein products mediate cellular redox homeostasis (Buetler et al., 1995; Hayes et al., 2000) . Consistent with impaired Nrf2 activation in PERK knockdown cells, expression of two distinct Nrf2 target genes, NQO1 (Itoh et al., 1997) and GCLC (Wild et al., 1999) , was decreased compared with the parental or control cells (Figure 7a ).
To address the role of Nrf2 downstream of PERK, we sought to define the site of PERK phosphorylation in Nrf2. Because PERK-dependent phosphorylation disrupts Nrf2-Keap1 binding, we focused on the Neh2 domain of Nrf2 that binds directly to Keap1 (Lo et al., 2006) . Indeed, PKC can phosphorylate serine 40 in this domain (Huang et al., 2002) . Purified recombinant PERK phosphorylated wild-type Nrf2-Neh2 and a serine 40 to alanine mutant; however, mutation of threonine 80 to alanine abrogated phosphorylation ( Figure 7b ). We confirmed stress-dependent phosphorylation of this residue in Nrf2 using a phospho-threonine reactive antibody (Figure 7c ). The threonine 80 is essential for Keap1-Nrf2 binding (Lo et al., 2006) , providing a biochemical basis for phosphorylationdependent disruption of the Keap1-Nrf2 interaction.
We then determined whether cellular phenotypes resulting from PERK loss could be rescued through enforced Nrf2 function. Nrf2 activity is restricted through its association with an E3 ligase, in which Keap1 functions as Nrf2-specific adaptor, thereby targeting Nrf2 to cullin 3 (Furukawa et al., 2003; Kobayashi et al., 2004; Zhang et al., 2004; Furukawa and Xiong, 2005) . We previously showed that basal levels of active Nrf2 can be elevated through either overexpression of Nrf2 or knockdown of Keap1 . Accordingly, expression of HA-Nrf2 restored normal growth to MDA-MB468 cells in which PERK was ablated (Figure 7d ). Consistent with its role in PERK-dependent regulation of redox homeostasis, introduction of HA-Nrf2 as well as Keap1 knockdown significantly attenuated oxidative DNA damage (Figures 7e and f) .
Dual role for PERK in tumorigenesis in vivo Using mouse models, we addressed two additional issues. First, we determined whether deletion of PERK attenuated MMTV-Neu-initiated tumorigenesis. MMTV-Neu transgenic mice were crossed with PERK loxP/loxP / MMTV-Cre mice (Bobrovnikova-Marjon et al., 2008) generating MMTV-Neu/PERK D/D . Mice that did not inherit the MMTV-Cre transgene, thereby retaining PERK, were used as controls (MMTV-Neu/PERK loxP/loxP ). Analysis of tumor-free survival revealed that PERK loss delayed MMTV-Neu-induced tumorigenesis (Figure 8a ). Tumor histology was characteristic of the MMTV-Neu mouse (Figure 8b ). PERK excision in mammary epithelium was assessed using immunoblot (Figure 8c Figure S5 ). Tumor formation was not due to outgrowth of cells showing inefficient PERK excision as only two tumors retained detectable PERK protein (Figure 8c ).
To determine whether Thr-80 phosphorylation of Nrf2 was dependent upon PERK in vivo, we immunoprecipitated Nrf2 from tumor lysates and assessed phosphothreonine levels. Reduced levels of phospho-threonine (Figure 8d ), suggesting that phosphorylation of Nrf2 in the tumor environment is a non-redundant function of PERK. Although use of the MMTV promoter to drive both PERK excision and oncogene expression permits targeting of the same cell population, it does not allow us to control the timing of perk excision with tumor onset. Our previous work revealed that perk is efficiently excised in the mammary gland of virgin mice by 4 months of age (Bobrovnikova-Marjon et al., 2008) . Because this is substantially before MMTV-Neu-induced tumor onset, we presumed that perk excision occurs before tumor initiation. We thus inferred that PERK loss delays tumor onset. To further address this possibility, we collected mammary glands from 9-to 14month-old MMTV-Neu/PERK loxP/loxP and MMTV-Neu/ PERK D/D mice to assess the onset of pre-malignant lesions. No pre-malignant lesions were identified in 9-month-old MMTV-Neu/PERK D/D mice (n ¼ 4), and one out of four mice showed a pre-neoplastic lesion in 12-to 14-month-old group (Figure 8e) . In contrast, hyperplastic lesions were apparent in MMTV-Neu/ PERK loxP/loxP mice at 9 and 14 months (Figure 8e ). Although tumor histology did not suggest that loss of PERK resulted in a less aggressive tumor, we also noted a twofold reduction in the incidence of lung metastases in PERK knockout mice (Figure 8f ). Mammary origin (Figure 8g ). Collectively, our data show that deletion of PERK delays Neu-dependent tumor onset and significantly reduces lung metastases.
DNA damage and activation of DDR may serve as a tumor barrier, although long-term genotoxic stress accompanied by mutational inactivation of DDR mechanisms is pro-tumorigenic (Bartkova et al., 2005; Gorgoulis et al., 2005; Stracker et al., 2008) . Thus, we considered whether PERK excision might trigger spontaneous mammary tumorigenesis. We used MMTV-Cre/PERK loxP/loxP mice (Bobrovnikova-Marjon et al., 2008) , and aged these animals for up to 24 months. During this interval, 6 of 29 animals developed overt mammary adenocarcinoma; in addition, premalignant adenomas were observed in several aged mice analyzed (Figure 8h ), whereas only 2 of 19 control PERK loxP/loxP mice developed carcinomas over this same interval. We noted amplification of the ErbB2 allele in two of six MMTV-Cre/PERK loxP/loxP animals using fluorescent in situ hybridization and confirmed the amplification in one of these tumors using quantitative RT-PCR (Figure 8i ). These findings show that longterm PERK inactivation could increase susceptibility to spontaneous tumor formation because of increased genomic instability.
Discussion
Because PERK facilitates cellular adaptation to reduced glucose and oxygen availability, challenges imposed by the tumor microenvironment, we investigated whether PERK is necessary for neoplastic growth. Our data reveal that loss of PERK triggers a significant attenuation of tumor cell proliferation because of increased oxidative DNA damage and cell cycle checkpoint activation. Reduced proliferation correlates with com-promised signaling through the PERK-responsive transcription factor Nrf2, implicating PERK/Nrf2 axis in promoting tumorigenesis. PERK substrates include eIF2a (Shi et al., 1998; Harding et al., 2000) and the Nrf2 transcription factor (Cullinan et al., 2003) . Previous work suggested that (Harding et al., 2003) and direct phosphorylation of Nrf2 by PERK . Nrf2 then regulates expression of enzymes necessary for the production of major cellular antioxidant, glutathione (Wild et al., 1999; Wild and Mulcahy, 2000; Shenvi et al., 2009) . Recent work showed that Nrf2 axis can be constitutively activated in tumors because of the inactivating mutations in Keap1 in breast (Nioi and Nguyen, 2007) and lung cancer , as well as mutations in Nrf2 leading to its aberrant accumulation (Shibata et al., 2008) . Furthermore, deletion of Nrf2 in alveolar epithelial cells resulted in accumulation of oxidized 8-oxoguanine DNA adducts, triggering DDR involving ATM, Chk1 and Chk2, and leading to G2/M cell cycle checkpoint activation (Reddy et al., 2008) . Finally, RNA interference-mediated inactivation of Nrf2 reduced tumorigenic potential of lung cancer cells (Singh et al., 2008) . However, this work contrasts with studies using the TRAMP (transgenic adenocarcinoma of the mouse prostate) mouse model of prostate cancer, which revealed that loss of Nrf2 is associated with increased cellular transformation because of elevated ROS levels and oxidative DNA damage (Frohlich et al., 2008) .
Our work supports a model in which targeted deletion of PERK in cancer cells results in inactivation of Nrf2 axis, leading to attenuation of tumor growth because of the accumulation of oxidized DNA adducts and DNA damage checkpoint activation. However, the potential contribution of impaired translational control through PERK-dependent regulation of eIF2a cannot be excluded (Back et al., 2009) . In our analysis, we did not always detect reduced levels of phospho-eIF2a in PERK-deficient tumors (Figure 8d ), suggesting compensatory regulation. Because phosphorylation of Nrf2 was impaired (Figure 8d ), we suggest that loss of Nrf2 activation in PERK-deficient cells largely contributes to the observed phenotype.
Recent investigation of PERK function during tumorigenesis has been paradoxical. Initial findings suggested that PERK potentiates the ability of transformed mouse embryo fibroblasts to grow as subcutaneous transplants (Bi et al., 2005; Blais et al., 2006) . In contrast, expression of a dominant-negative PERK allele in immortalized MCF10A normal mammary epithelial cells contributed to neoplastic growth that was associated with increased levels of ErbB2 expression (Sequeira et al., 2007) . We used the shRNA approach to reduce PERK levels in human cancer cells and Cre/loxP system to excise perk in murine mammary epithelium and mammary tumors. Both approaches revealed that PERK deficiency significantly compromises growth of established tumors in vivo.
We found that loss of PERK significantly impaired cellular ROS buffering mechanisms, resulting in oxidative DNA damage and subsequent engagement of the DDR checkpoint. Activation of the DDR checkpoint has been correlated with tumor suppression (Bartkova et al., 2005; Gorgoulis et al., 2005; Stracker et al., 2008) . Indeed, we observed that PERK loss attenuated tumor onset and expansion, the conditions that are generally associated with high levels of ROS accumulation because of oncogene activation (Behrend et al., 2003) or hypoxia (Guzy and Schumacker, 2006; Clanton, 2007; Liu et al., 2008) , respectively. Interestingly, in normal mammary tissue, loss of PERK function did not have a dramatic consequence, perhaps reflective of normal homeostatic proliferation that does not induce generation of significant mitochondrial ROS (Nicco et al., 2005) . Ultimately, unabated DNA damage can override the DNA damage checkpoint, resulting in fortuitous mutations that promote neoplastic growth. Accordingly, over the lifetime of an organism, PERK inactivation did contribute to genomic instability, thereby increasing tumor susceptibility as noted by the increased frequency of spontaneous mammary carcinomas occurring in aged PERK-null mammary glands.
Although loss of PERK triggers a DDR, tumor cells eventually escape the checkpoint permitting restoration of cell proliferation in vitro and in vivo, however at a reduced rate. Checkpoint activation can be averted through mutagenesis and/or inactivation of the DDR pathway components, such as ATM (Tommiska et al., 2008) , Chk2 (Wu et al., 2001) or upregulation of CDC25 family of phosphatases in tumor cells (Wu et al., 1998; Evans, 2000) . Accordingly, analysis of DNA damage signaling components in MMTV-Neu/PERK D/D and control MMTV-Neu/PERK loxP/loxP mice revealed that pTyr15 CDK2 levels and CDC25A levels were generally higher in the PERK-null background (Supplementary Figure S6 ). Furthermore, PERK deficiency-induced cell cycle delay was hampered in HCT116 cells that have reduced ATM expression because of the promoter hypermethylation. However, HCT116 cells deficient for ATM downstream target Chk2 showed a G2/M cell cycle delay because of the activation of ATR/Chk1 pathway, suggesting that Chk2 signaling may promote the repair of DSBs, whereas unrepaired DNA damage triggers replicative stress. Together, these findings underscore the complexity of the DDR regulatory mechanisms and warrant further detailed investigation of the PERK and DDR pathway interconnections.
In summary, PERK regulates cancer cell redox homeostasis through buffering ROS accumulation and thereby preventing activation of oxidative DNA damage checkpoint. Loss of PERK in cancer cells suppresses tumor onset and expansion, whereas it increases genomic instability in normal cells and may result in tumor development. In the context of therapeutic intervention, inhibition of PERK may result in a highly effective novel therapeutic approach when combined with agents that increase DNA damage burden.
Materials and methods
Animals and tissue
Experiments were conducted in accordance with the Animal Welfare Act and the Department of Health and Human Services Guide. Mammary gland-specific perk knockout animals (Bobrovnikova-Marjon et al., 2008) were mated to mice bearing the Neu transgene under the control of MMTV-LTR promoter (Jackson Laboratories, Bar Harbor, ME, USA; Guy et al., 1992) . The Neu and Cre transgene bearing offspring were bred to homozygocity for the LoxP allele of perk, thus generating mammary gland-specific perk 'null'. Littermates bearing Neu but not the Cre transgene were used as controls. The No. 4 inguinal gland was extracted and processed for whole-mount analysis as previously described (Lin et al., 2008) .
Cell culture MDA-MB468 and T47D cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS), 0.01 mg/ml insulin and antibiotics. TE3, TE7 and KYSE-520 were grown in RPMI-1640 supplemented with 2 mM L-glutamine, 10% FBS and antibiotics. Tumor-derived mammary epithelial cell lines were derived and cultured as described (Lin et al., 2008) .
Immunoprecipitation and immunoblotting
Cells were lysed in EBC buffer (50 mM Tris pH 8.0, 120 mM NaCl and 0.5% NP-40) supplemented with protease and phosphatase inhibitors. Antibodies used for immunobloting analysis, immunofluorescence and immunohistochemistry included PERK (Rockland, Gilbertsville, PA, USA); human ATF4, histone H3 (tri methyl K9) and phospho-Chk2 (Thr68) (Abcam, Cambridge, MA, USA); human CHOP (Affinity, Golden, CO, USA), b-actin (Sigma, St Louis, MO, USA, AC-15), Nrf2, Keap 1, CDK2 and p19 ARF (Santa Cruz Biotechnology, Santa Cruz, CA, USA); g-H2AX (Ser139), phospho-eIF2a, eIF4E, phospho-Tyr15 CDK2 and phospho-Thr (Cell Signaling, Danvers, MA, USA); troma-1 (Developmental Studies Hybridoma Bank, University of Iowa), ErbB2 (Calbiochem, San Diego, CA, USA), Chk2 (BD Pharmingen, San Diego, CA, USA), eIF2a (BioSource, Camarillo, CA, USA) and phospho-ATM (Millipore, Billerica, MA, USA).
Lentivirus, retrovirus shRNA/small interfering RNA 293T cells were transfected with PMDL, VSVG, REV and pLKO.1 containing shRNA against PERK (IDTRCN0000001401; Open Biosystems, Huntsville, AL, USA) or pLKO.1 empty vector as control using Lipofectamine Plus (Invitrogen, Carlsbad, CA, USA) for stable knockdown or FuGene (Roche, Indianapolis, IN, USA) for acute knockdown experiments. Viral supernatants were harvested 48 h after transfection and concentrated using SW-28 rotor (Beckman Coulter, Brea, CA, USA) for stable knockdown infections. Retroviruses were produced as previously described (Brewer and Diehl, 2000) . MDA-MB468 PERK knockdown cells were transfected with Scrambled and keap1-specific small interfering RNA (Dharmacon, Lafayette, CO, USA) using HiPerfect (Qiagen, Valencia, CA, USA). Experiments were conducted 72 h after transfection.
Growth curves
Cells (3 Â 10 4 ) were plated in 60 mm dish. Cells were counted every 24 h using hemocytometer. ROS scavenger, N-acetylcysteine, was used at 5 mM where indicated. Culture media was changed every 3 days. Each experiment was performed in triplicate.
RT-PCR
RNA was prepared from cultured cells or frozen tissues using TRIzol (Invitrogen), followed by isopropanol precipitation. Genomic DNA was isolated using Qiagen DNeasy kit. Quantitative RT-PCR reactions were performed using SYBR Green (SuperArray, Frederick, MD, USA). Primer sequences are available upon request. PERK excision efficiency was determined semiquantitative RT-PCR as described (Zhang et al., 2006a) .
Immunofluorescence
Cells were permeabilized with ice-cold methanol/acetone (1:1) for 10 min at À20 1C, allowed to air dry, rehydrated with phosphate-buffered saline, and blocked in 10% FBS/PBS for 40 min. Primary and secondary antibodies were diluted in 10% FBS/PBS and incubated for 2 h or 30 min at room temperature, respectively.
Fluorescent in situ hybridization
Fluorescent in situ hybridization for ErbB2 was performed on paraffin sections after treatment with proteinase K. Biotinlabeled probe was generated by random priming method with ErbB2 full-length complementary DNA (ID 5356166; Open Biosystems) and visualized using streptavidin-Texas Red.
ROS measurement
Cells were incubated with 5 mM 5-(and-6)-chloromethyl-2 0 ,7 0dichlorodihydrofluorescein diacetate, acetyl ester (CM-H 2 DCFDA, Invitrogen) for 30 min in the dark at 37 1C, washed with PBS, trypsinized and analyzed using fluorescenceactivated cell sorting.
8-oxyguanine staining
Cells (4 Â 10 5 ) were grown on glass coverslips, permeabilized with methanol/acetone (1:1), and 8-oxyguanine was detected using OxyDNA test (Biotrin, Mount Merrion Co, Dublin, Ireland). For tumor sections, antigen retrieval was performed by heating in 50 mM Tris pH 9.5 for 12 min. Slides were immersed in ice-cold methanol for 10 min at À20 1C. Sections were blocked with 10% FBS/PBS and incubated overnight at 4 1C with fluorescein-isothiocyanate conjugate in wash solution.
Comet assay DNA fragmentation was tested by alkaline electrophoresis comet assay (Trevigen, Gaithersburg, MD, USA) according to the manufacturer's instructions. Data were analyzed using Comet assay IV software (Perceptive Instruments, Suffold, UK).
Orthotopic injections
Cells (5 Â 10 6 ) were mixed with 30 ml matrigel/media (1:1) and injected into the mammary fat pad of 3-month-old female severe combined immunodeficient mice (Charles River, Wilmington, MA, USA). Animals were euthanized after 37 (human cells) or 28 (mouse cells) days. Tumor size was measured using a caliper, and tumor volume was calculated using the formula: volume (cm 3 ) ¼ p Â (length) Â (width) 2 /6 (Bruns et al., 2004) .
Immunohistochemistry
Antigen retrieval was performed in 10 mM citrate buffer, pH 6.0 (Biogenex, San Ramon, CA, USA). Endogenous peroxidase activity was blocked with 3% peroxide in methanol. Sections were blocked with 1X Power Block Reagent (Biogenex). Detection was performed with biotinylated secondary antibodies and ABC-HRP reagent followed by 3,3 0diaminobenzidine substrate (Vector Laboratories, Burlingame, CA, USA).
In vitro kinase assay Cells or tissues were solubilized in EBC buffer. CDK2 complexes were isolated by precipitation with a CDK2 reactive antibody from 200 mg total protein. The kinase assay was performed using recombinant histone H1 with 10 mCi of g-32 P-ATP for 10 min at 30 1C. Reactions were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to polyvinylidene fluoride membrane and visualized using autoradiography.
Cell cycle analysis
Cells were pulsed with 10 mM 5-bromodeoxyuridine 45 min before being harvested. Cells were washed with PBS, fixed with ethanol and stained with anti-5-bromodeoxyuridine (BD Pharmingen) and fluorescein-isothiocyanate-conjugated secondary antibody (BD Pharmingen) and then with propidium iodide (10 mg/ml) for 30 min before fluorescence-activated cell sorting analysis. Cell cycle profiles based on DNA content and 5-bromodeoxyuridine incorporation were assessed using FlowJo software (Ashland, OR, USA).
